Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.
about
Recent advances in the development of vaccines for tuberculosisMulti-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models.Novel vaccination approaches to prevent tuberculosis in childrenAntiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T CellsA Mycobacterium tuberculosis Dormancy Antigen Differentiates Latently Infected Bacillus Calmette-Guérin-vaccinated Individuals.Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidatesCurrent status of new tuberculosis vaccine in children.New Genome-Wide Algorithm Identifies Novel In-Vivo Expressed Mycobacterium Tuberculosis Antigens Inducing Human T-Cell Responses with Classical and Unconventional Cytokine Profiles.Mycobacterium tuberculosis: 2014 Clinical trials in reviewAnimal models in tuberculosis research - where is the beef?Towards new TB vaccines: What are the challenges?Global Efforts in the Development of Vaccines for Tuberculosis: Requirements for Improved Vaccines Against Mycobacterium tuberculosis.Vaccine research and development: tuberculosis as a global health threat.A Multistage Subunit Vaccine Effectively Protects Mice Against Primary Progressive Tuberculosis, Latency and Reactivation.Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of three protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection.Polyfunctional CD4+ T Cells As Targets for Tuberculosis VaccinationEffects of KLK Peptide on Adjuvanticity of Different ODN SequencesApplication of Pharmacokinetics Modelling to Predict Human Exposure of a Cationic Liposomal Subunit Antigen Vaccine System.Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost?A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.The current status, challenges, and future developments of new tuberculosis vaccines.Vaccines for Leprosy and Tuberculosis: Opportunities for Shared Research, Development, and Application.Identification of protective postexposure mycobacterial vaccine antigens using an immunosuppression-based reactivation model in the zebrafish.Development of New Preventive and Therapeutic Vaccines for Tuberculosis.Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making
P2860
Q26796440-26A3228E-4892-40E4-8F3F-26B5E2E4DB79Q33614952-79624679-FA42-45C1-BFA1-67843E94FB02Q33801426-E2E94E94-903A-4B9A-8F84-7C0464F75411Q35773892-7D485317-D8D9-4CA5-BBB5-C5ACDD30E765Q36038593-35C8D207-0A41-4F87-912E-8DC428F2A213Q36909492-5DE17D02-A868-4999-ACCE-CA60E792A99EQ37130796-3BE30E9F-8F3E-466A-A3BA-A961265D9EE2Q37445202-A7E20589-B00E-439B-B7D7-3FAF7ACE07BFQ38387116-1EF86D86-CF24-4E97-B7F4-29AFF2216ADAQ38527417-623A6AEA-3377-4D90-B259-6639EBA530C4Q38767468-9F2DB686-B9AD-4890-98B6-2E70B743AFB5Q38907507-F29194D4-3B92-4796-80CA-026AC4DEF8F0Q40059597-19CE386E-D21B-4BA1-BD94-A06FFA9868B6Q40133620-82948F51-5F44-4D8F-92DA-5324BD2AB9E5Q41995267-BC077FFE-CDB0-4A1A-9829-534FF5BFAA1CQ42373425-BBE76296-19A3-4307-B193-5B24BDA17331Q42434134-2B1C512C-AFBF-4592-A4BC-C02365322A83Q47351571-C60EE424-6F1A-42F8-8F9C-E3A35F4637C7Q47834561-A94D1E75-4DD7-40F2-AB00-46C9D83B26D2Q48268531-5FEB6DBA-0968-4647-8E58-7537DA0C2829Q52337140-E7AFA8B2-319F-48DD-B4E4-8C282B0B32A3Q52657152-1670CE17-24E4-4CBA-93E6-86ED7E7FF451Q54246706-43DB237A-94B6-42C4-AFBC-252D787F75FCQ55280574-08C2C621-2570-41D1-BDF7-F8F613302585Q58375482-676F4CDA-61A0-4F77-B334-6B6426C35770
P2860
Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Safety and immunogenicity of H ...... zed, placebo-controlled trial.
@ast
Safety and immunogenicity of H ...... zed, placebo-controlled trial.
@en
Safety and immunogenicity of H ...... zed, placebo-controlled trial.
@nl
type
label
Safety and immunogenicity of H ...... zed, placebo-controlled trial.
@ast
Safety and immunogenicity of H ...... zed, placebo-controlled trial.
@en
Safety and immunogenicity of H ...... zed, placebo-controlled trial.
@nl
prefLabel
Safety and immunogenicity of H ...... zed, placebo-controlled trial.
@ast
Safety and immunogenicity of H ...... zed, placebo-controlled trial.
@en
Safety and immunogenicity of H ...... zed, placebo-controlled trial.
@nl
P2093
P2860
P50
P921
P1433
P1476
Safety and immunogenicity of H ...... zed, placebo-controlled trial.
@en
P2093
Christian Pohl
Claudia Daubenberger
Elirehema Mfinanga
Elisabeth J Hughes
Hannah Jeffery
Ingrid Kromann
Klaus Reither
Lynn Katsoulis
Nicole Lenz
Nicolene Gardiner
P2860
P304
P356
10.1371/JOURNAL.PONE.0114602
P407
P50
P577
2014-12-09T00:00:00Z